Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study

Charles Béguelin; Nicole Friolet; Darius Moradpour; Roland Sahli; Franziska Suter-Riniker; Alexander Lüthi; Matthias Cavassini; Huldrych F. Günthard; Manuel Battegay; Enos Bernasconi; Patrick Schmid; Alexandra Calmy; Andrew Atkinson; Andri Rauch; Gilles Wandeler

doi:10.1093/cid/cix125

Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study

Charles Béguelin, Nicole Friolet, Darius Moradpour, Roland Sahli, Franziska Suter-Riniker, Alexander Lüthi, Matthias Cavassini, Huldrych F. Günthard, Manuel Battegay, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Andrew Atkinson, Andri Rauch, Gilles Wandeler

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.

Original language	English
Pages (from-to)	1275-1278
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	64
Issue number	9
DOIs	https://doi.org/10.1093/cid/cix125
State	Published - May 1 2017

Keywords

Coinfection
Hepatitis delta virus
Human immunodeficiency virus
Replication
Tenofovir

Access to Document

10.1093/cid/cix125

Cite this

Béguelin, C., Friolet, N., Moradpour, D., Sahli, R., Suter-Riniker, F., Lüthi, A., Cavassini, M., Günthard, H. F., Battegay, M., Bernasconi, E., Schmid, P., Calmy, A., Atkinson, A., Rauch, A., & Wandeler, G. (2017). Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 64(9), 1275-1278. https://doi.org/10.1093/cid/cix125

@article{59ef26ff3862476b92bb5e6adc08acee,

title = "Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study",

abstract = "We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.",

keywords = "Coinfection, Hepatitis delta virus, Human immunodeficiency virus, Replication, Tenofovir",

author = "Charles B{\'e}guelin and Nicole Friolet and Darius Moradpour and Roland Sahli and Franziska Suter-Riniker and Alexander L{\"u}thi and Matthias Cavassini and G{\"u}nthard, {Huldrych F.} and Manuel Battegay and Enos Bernasconi and Patrick Schmid and Alexandra Calmy and Andrew Atkinson and Andri Rauch and Gilles Wandeler",

note = "Publisher Copyright: {\textcopyright} The Author 2017.",

year = "2017",

month = may,

day = "1",

doi = "10.1093/cid/cix125",

language = "English",

volume = "64",

pages = "1275--1278",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

number = "9",

}

Béguelin, C, Friolet, N, Moradpour, D, Sahli, R, Suter-Riniker, F, Lüthi, A, Cavassini, M, Günthard, HF, Battegay, M, Bernasconi, E, Schmid, P, Calmy, A, Atkinson, A, Rauch, A & Wandeler, G 2017, 'Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study', Clinical Infectious Diseases, vol. 64, no. 9, pp. 1275-1278. https://doi.org/10.1093/cid/cix125

TY - JOUR

T1 - Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study

AU - Béguelin, Charles

AU - Friolet, Nicole

AU - Moradpour, Darius

AU - Sahli, Roland

AU - Suter-Riniker, Franziska

AU - Lüthi, Alexander

AU - Cavassini, Matthias

AU - Günthard, Huldrych F.

AU - Battegay, Manuel

AU - Bernasconi, Enos

AU - Schmid, Patrick

AU - Calmy, Alexandra

AU - Atkinson, Andrew

AU - Rauch, Andri

AU - Wandeler, Gilles

PY - 2017/5/1

Y1 - 2017/5/1

N2 - We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.

AB - We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.

KW - Coinfection

KW - Hepatitis delta virus

KW - Human immunodeficiency virus

KW - Replication

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=85020037422&partnerID=8YFLogxK

U2 - 10.1093/cid/cix125

DO - 10.1093/cid/cix125

M3 - Article

C2 - 28199492

AN - SCOPUS:85020037422

SN - 1058-4838

VL - 64

SP - 1275

EP - 1278

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this